QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.104.002576v1 33/5/672    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mori, A. Articles by Takeuchi, Y. Search for Related Content PubMed PubMed Citation Articles by Mori, A. Articles by Takeuchi, Y. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Hazardous Substances DB CLOZAPINE

UDP-GLUCURONOSYLTRANSFERASE 1A4 POLYMORPHISMS IN A JAPANESE POPULATION AND KINETICS OF CLOZAPINE GLUCURONIDATION

Department of Pediatrics (A.M., Y.M., M.I., Y.T.); and Bioscience (H.S.), Shiga University of Medical Science, Shiga, Japan

The UDP-glucuronosyltransferase (UGT) family plays a major role in the excretion of endobiotics and xenobiotics and their metabolites. Human UGT1A4 catalyzes the glucuronidation of primary, secondary, and tertiary amines, sapogenins, androgens, and progestins. We directly sequenced polymerase chain reaction-amplified fragments of the UGT1A4 gene from 100 healthy adult Japanese volunteers and calculated their mutation frequency. We identified four single nucleotide polymorphisms (SNPs): three in exon 1 (142T>G: L48V, 448T>C: L150L, 804G>A: P268P), and one in intron 1 (867 + 43C>T). We found three types of alleles with distinct SNP combinations that coded for different amino acid sequences: L48V-L150L-P268P-867 + 43C>T (frequency, 0.155), L48V (0.01), and P268P (0.01) (wild-type frequency was 0.825). The L48V mutant gave twice the efficiency (V_max/K_m) for the antipsychotic drug clozapine as the wild-type. Efficiencies of L48V for trans-androsterone, imipramine, and cyproheptadine were increased, but the efficiency for tigogenin was reduced. L48V therefore increased or decreased the glucuronidation activity, depending upon the substrates. This study shows the importance of identifying patients with the L48V polymorphism when calculating dosage, and when considering the potential adverse effects of drugs that are substrates of UGT1A4.

This article has been cited by other articles:

				A. K. Yocum and A. M. Chinnaiyan Current affairs in quantitative targeted proteomics: multiple reaction monitoring-mass spectrometry Brief Funct Genomic Proteomic, March 11, 2009; (2009) eln056v1. [Abstract] [Full Text] [PDF]

				K. P. Kanebratt and T. B. Andersson Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies Drug Metab. Dispos., July 1, 2008; 36(7): 1444 - 1452. [Abstract] [Full Text] [PDF]

				T. Kubota, B. C. Lewis, D. J. Elliot, P. I. Mackenzie, and J. O. Miners Critical Roles of Residues 36 and 40 in the Phenol and Tertiary Amine Aglycone Substrate Selectivities of UDP-Glucuronosyltransferases 1A3 and 1A4 Mol. Pharmacol., October 1, 2007; 72(4): 1054 - 1062. [Abstract] [Full Text] [PDF]

				S. J. Miyagi and A. C. Collier Pediatric Development of Glucuronidation: The Ontogeny of Hepatic UGT1A4 Drug Metab. Dispos., September 1, 2007; 35(9): 1587 - 1592. [Abstract] [Full Text] [PDF]

				Y. Chen, S. Chen, X. Li, X. Wang, and S. Zeng Genetic Variants of Human UGT1A3: Functional Characterization and Frequency Distribution in a Chinese Han Population Drug Metab. Dispos., September 1, 2006; 34(9): 1462 - 1467. [Abstract] [Full Text] [PDF]